Biologics at Teva

Biopharmaceutical therapies have transformed the way many diseases are treated. They have, and continue to, revolutionize treatment outcomes for patients across a broad range of conditions. Teva is working hard to realize the full promise of these remarkable medicines.
Biologics at Teva

Improving Access, Improving Outcomes

We intend to do this by increasing access to vital medicines through affordability, innovation and improved treatment outcomes. Our aim is to offer fresh hope to patients through discovery and development of novel biopharmaceuticals based on new targets and pathways.
In short, we are working to build a balanced portfolio of innovative Biologics, Biobetters and Biosimilars that is aligned to our core therapeutic areas of expertise.

Building on Success

We have a track record of success in the biologics arena, having launched Granix® (tbo-filgrastim) in the US and Lonquex® (lipegfilgrastim) in Europe and we plan to continue building on that success by turning key insights into novel and highly differentiated therapies.
Our biologics pipeline includes multiple product candidates in various stages of development including both novel monoclonal antibody therapeutics and albumin fusion technology-based programs.

Novel Biologics

We are furthering the discovery and development of novel biopharmaceuticals for the treatment of numerous diseases. Using proprietary novel technologies and validated targets, we are developing new drug candidates that align with key therapeutic areas.
Our biologics discovery group is also working on platforms and technologies that are designed to enhance the specificity and delivery of antibodies in a way that will maximize their effect.

Biobetters

Our R&D group also spearheads the development of next-generation peptide and protein based therapeutics across a variety of therapeutic categories. Our aims are improved efficacy, reduced dosing frequency and enhanced patient safety and convenience. Through the use of advanced technology platforms, we can improve and expand the use of established biopharmaceuticals as we meet the challenge of optimizing complex manufacturing processes.

Differentiated Biosimilars

We are a leader in the development of Biosimilar medicines. As the equivalent to generics for name-brand biologics, Biosimilars offer patients and healthcare systems access to high-cost medicines at a more affordable level. Our R&D group has adopted a selective approach to developing Biosimilars, and applies novel thinking in our determination to make these medicines available to those patients who need them.